![]() ![]() It compared the effects of aspirin and a placebo in people over the age of 70 without a medical condition that required aspirin. Published in the New England Journal of Medicine today, the ASPirin in Reducing Events in the Elderly ( ASPREE) trial was the largest and most comprehensive clinical trial conducted in Australia. This has increased the need to resolve whether aspirin in the healthy elderly actually prolongs their good health. With the growing proportion of elderly people in our community, a major focus of preventive medicine is to maintain the independence of this age-group for as long as possible. Read more: How Australians Die: cause #1 – heart diseases and stroke Yet, many healthy older people continued being prescribed aspirin for this purpose. And it had been apparent since the 1990s there was a lack of adequate evidence to support the use of low-dose aspirin in healthy older people. It has long been established that aspirin saves lives when taken by people after a cardiac event such as a heart attack. However it does increase the risk of major bleeding. ![]() We also found daily low-dose aspirin does not prevent heart attack or stroke when taken by elderly people who hadn’t experienced either condition before. This was one finding from our seven-year study that included more than 19,000 older people from Australia and the US. Taking low-dose aspirin daily doesn’t preserve good health or delay the onset of disability or dementia in healthy older people. ).Daily low-dose aspirin doesn’t reduce heart-attack risk in healthy peopleįor decades, doctors have been prescribing low-dose aspirin for healthy people over the age of 70. ![]() (Funded by the European Union Seventh Framework Program and the Fetal Medicine Foundation EudraCT number, 2013-003778-29 Current Controlled Trials number, ISRCTN13633058. Treatment with low-dose aspirin in women at high risk for preterm preeclampsia resulted in a lower incidence of this diagnosis than placebo. There were no significant between-group differences in the incidence of neonatal adverse outcomes or other adverse events. Adherence was good, with a reported intake of 85% or more of the required number of tablets in 79.9% of the participants. Results were materially unchanged in a sensitivity analysis that took into account participants who had withdrawn or were lost to follow-up. Preterm preeclampsia occurred in 13 participants (1.6%) in the aspirin group, as compared with 35 (4.3%) in the placebo group (odds ratio in the aspirin group, 0.38 95% confidence interval, 0.20 to 0.74 P=0.004). The analysis was performed according to the intention-to-treat principle.Ī total of 152 women withdrew consent during the trial, and 4 were lost to follow up, which left 798 participants in the aspirin group and 822 in the placebo group. The primary outcome was delivery with preeclampsia before 37 weeks of gestation. In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1776 women with singleton pregnancies who were at high risk for preterm preeclampsia to receive aspirin, at a dose of 150 mg per day, or placebo from 11 to 14 weeks of gestation until 36 weeks of gestation. It is uncertain whether the intake of low-dose aspirin during pregnancy reduces the risk of preterm preeclampsia. Preterm preeclampsia is an important cause of maternal and perinatal death and complications. 1 From King's College Hospital (D.L.R., L.C.P., N.O., A.S., R.A., K.H.N.), Homerton University Hospital (S.C.), North Middlesex University Hospital (D.J.), and University College London Comprehensive Clinical Trials Unit (K.M.), London, University of Exeter, Exeter (D.W.), Medway Maritime Hospital, Gillingham (R.A.), and Southend University Hospital, Westcliff-on-Sea (M.S.) - all in the United Kingdom Chinese University of Hong Kong, Hong Kong (L.C.P.) Hospital Clínico Universitario Virgen de la Arrixaca, Murcia (C.P.M.), Hospital Universitario San Cecilio, Granada (F.S.M.), and Hospiten Group, Tenerife (W.P.) - all in Spain Ospedale Maggiore Policlinico, Milan (N.P.) University Hospital Brugmann, Université Libre de Bruxelles, Brussels (J.C.J.) Attikon University Hospital, Athens (G.P.) Rabin Medical Center, Petach Tikva (K.T.-G.), and HyLabs Diagnostics, Rehovot (H.M.) - both in Israel and University of Iceland, Reykjavik (S.G.). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |